vs
安进（AMGN）与SYNTEC OPTICS HOLDINGS, INC.（OPTX）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是SYNTEC OPTICS HOLDINGS, INC.的1314.5倍（$9.9B vs $7.5M）。安进净利率更高（13.5% vs -4.6%，领先18.1%）。安进同比增速更快（8.6% vs 2.5%）。安进自由现金流更多（$961.0M vs $-4.4K）。过去两年安进的营收复合增速更高（15.1% vs 9.5%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
AMGN vs OPTX — 直观对比
营收规模更大
AMGN
是对方的1314.5倍
$7.5M
营收增速更快
AMGN
高出6.1%
2.5%
净利率更高
AMGN
高出18.1%
-4.6%
自由现金流更多
AMGN
多$961.0M
$-4.4K
两年增速更快
AMGN
近两年复合增速
9.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $7.5M |
| 净利润 | $1.3B | $-343.8K |
| 毛利率 | 69.8% | 23.6% |
| 营业利润率 | 27.6% | 4.2% |
| 净利率 | 13.5% | -4.6% |
| 营收同比 | 8.6% | 2.5% |
| 净利润同比 | 112.6% | 77.7% |
| 每股收益（稀释后） | $2.45 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNOPTX
| Q4 25 | $9.9B | $7.5M | ||
| Q3 25 | $9.6B | $7.0M | ||
| Q2 25 | $9.2B | $6.6M | ||
| Q1 25 | $8.1B | $7.1M | ||
| Q4 24 | $9.1B | $7.3M | ||
| Q3 24 | $8.5B | $7.9M | ||
| Q2 24 | $8.4B | $7.0M | ||
| Q1 24 | $7.4B | $6.3M |
净利润AMGNOPTX
| Q4 25 | $1.3B | $-343.8K | ||
| Q3 25 | $3.2B | $-1.4M | ||
| Q2 25 | $1.4B | $-343.9K | ||
| Q1 25 | $1.7B | $323.7K | ||
| Q4 24 | $627.0M | $-1.5M | ||
| Q3 24 | $2.8B | $-13.3K | ||
| Q2 24 | $746.0M | $281.8K | ||
| Q1 24 | $-113.0M | $-1.2M |
毛利率AMGNOPTX
| Q4 25 | 69.8% | 23.6% | ||
| Q3 25 | 67.8% | 12.3% | ||
| Q2 25 | 67.2% | 24.4% | ||
| Q1 25 | 63.6% | 32.7% | ||
| Q4 24 | 65.7% | 13.5% | ||
| Q3 24 | 61.1% | 23.3% | ||
| Q2 24 | 61.4% | 31.0% | ||
| Q1 24 | 57.0% | 11.3% |
营业利润率AMGNOPTX
| Q4 25 | 27.6% | 4.2% | ||
| Q3 25 | 26.4% | -17.5% | ||
| Q2 25 | 28.9% | -2.2% | ||
| Q1 25 | 14.5% | 7.5% | ||
| Q4 24 | 25.4% | -19.6% | ||
| Q3 24 | 24.1% | 1.4% | ||
| Q2 24 | 22.8% | 2.3% | ||
| Q1 24 | 13.3% | -22.5% |
净利率AMGNOPTX
| Q4 25 | 13.5% | -4.6% | ||
| Q3 25 | 33.7% | -20.6% | ||
| Q2 25 | 15.6% | -5.2% | ||
| Q1 25 | 21.2% | 4.6% | ||
| Q4 24 | 6.9% | -21.0% | ||
| Q3 24 | 33.3% | -0.2% | ||
| Q2 24 | 8.9% | 4.0% | ||
| Q1 24 | -1.5% | -19.3% |
每股收益（稀释后）AMGNOPTX
| Q4 25 | $2.45 | $-0.01 | ||
| Q3 25 | $5.93 | $-0.04 | ||
| Q2 25 | $2.65 | $-0.01 | ||
| Q1 25 | $3.20 | $0.01 | ||
| Q4 24 | $1.17 | $-0.05 | ||
| Q3 24 | $5.22 | $0.00 | ||
| Q2 24 | $1.38 | $0.01 | ||
| Q1 24 | $-0.21 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | — |
| 总债务越低越好 | $54.6B | $2.6M |
| 股东权益账面价值 | $8.7B | $9.5M |
| 总资产 | $90.6B | $24.3M |
| 负债/权益比越低杠杆越低 | 6.31× | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资AMGNOPTX
| Q4 25 | $9.1B | — | ||
| Q3 25 | $9.4B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $12.0B | — | ||
| Q3 24 | $9.0B | — | ||
| Q2 24 | $9.3B | — | ||
| Q1 24 | $9.7B | — |
总债务AMGNOPTX
| Q4 25 | $54.6B | $2.6M | ||
| Q3 25 | $54.6B | $2.7M | ||
| Q2 25 | $56.2B | $2.9M | ||
| Q1 25 | $57.4B | $3.0M | ||
| Q4 24 | $60.1B | $3.1M | ||
| Q3 24 | $60.4B | $3.2M | ||
| Q2 24 | $62.6B | $2.8M | ||
| Q1 24 | $64.0B | $3.0M |
股东权益AMGNOPTX
| Q4 25 | $8.7B | $9.5M | ||
| Q3 25 | $9.6B | $9.8M | ||
| Q2 25 | $7.4B | $11.0M | ||
| Q1 25 | $6.2B | $11.4M | ||
| Q4 24 | $5.9B | $11.0M | ||
| Q3 24 | $7.5B | $12.1M | ||
| Q2 24 | $5.9B | $12.1M | ||
| Q1 24 | $5.0B | $11.9M |
总资产AMGNOPTX
| Q4 25 | $90.6B | $24.3M | ||
| Q3 25 | $90.1B | $24.6M | ||
| Q2 25 | $87.9B | $25.3M | ||
| Q1 25 | $89.4B | $26.3M | ||
| Q4 24 | $91.8B | $26.0M | ||
| Q3 24 | $90.9B | $27.3M | ||
| Q2 24 | $90.9B | $25.8M | ||
| Q1 24 | $93.0B | $24.6M |
负债/权益比AMGNOPTX
| Q4 25 | 6.31× | 0.28× | ||
| Q3 25 | 5.67× | 0.28× | ||
| Q2 25 | 7.57× | 0.26× | ||
| Q1 25 | 9.24× | 0.26× | ||
| Q4 24 | 10.23× | 0.28× | ||
| Q3 24 | 8.02× | 0.26× | ||
| Q2 24 | 10.57× | 0.23× | ||
| Q1 24 | 12.75× | 0.25× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $-3.9K |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $-4.4K |
| 自由现金流率自由现金流/营收 | 9.7% | -0.1% |
| 资本支出强度资本支出/营收 | 6.5% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.20× | — |
| 过去12个月自由现金流最近4个季度 | $8.1B | $28.3K |
8季度趋势，按日历期对齐
经营现金流AMGNOPTX
| Q4 25 | $1.6B | $-3.9K | ||
| Q3 25 | $4.7B | $535.3K | ||
| Q2 25 | $2.3B | $-158.0K | ||
| Q1 25 | $1.4B | $299.3K | ||
| Q4 24 | $4.8B | $623.8K | ||
| Q3 24 | $3.6B | $417.3K | ||
| Q2 24 | $2.5B | $-1.7M | ||
| Q1 24 | $689.0M | $-289.8K |
自由现金流AMGNOPTX
| Q4 25 | $961.0M | $-4.4K | ||
| Q3 25 | $4.2B | $496.3K | ||
| Q2 25 | $1.9B | $-548.1K | ||
| Q1 25 | $980.0M | $84.6K | ||
| Q4 24 | $4.4B | $12.1K | ||
| Q3 24 | $3.3B | $43.8K | ||
| Q2 24 | $2.2B | $-1.9M | ||
| Q1 24 | $459.0M | $-385.1K |
自由现金流率AMGNOPTX
| Q4 25 | 9.7% | -0.1% | ||
| Q3 25 | 44.4% | 7.1% | ||
| Q2 25 | 20.8% | -8.4% | ||
| Q1 25 | 12.0% | 1.2% | ||
| Q4 24 | 48.4% | 0.2% | ||
| Q3 24 | 39.0% | 0.6% | ||
| Q2 24 | 26.5% | -26.5% | ||
| Q1 24 | 6.2% | -6.2% |
资本支出强度AMGNOPTX
| Q4 25 | 6.5% | 0.0% | ||
| Q3 25 | 4.6% | 0.6% | ||
| Q2 25 | 4.0% | 5.9% | ||
| Q1 25 | 5.0% | 3.0% | ||
| Q4 24 | 4.1% | 8.4% | ||
| Q3 24 | 3.0% | 4.7% | ||
| Q2 24 | 2.8% | 2.3% | ||
| Q1 24 | 3.1% | 1.5% |
现金转化率AMGNOPTX
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | — | ||
| Q1 25 | 0.80× | 0.92× | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 3.30× | -6.01× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
OPTX
暂无分部数据
